This is an aggregated industry headline. Read the full story at PharmaVoice →
A new Westlake-backed biotech takes aim at migraines
Vedana Therapeutics recently emerged from stealth with $46 million to support its mission of developing "anti-PACAP" therapies, an increasingly popular strategy for migraine prevention.
By PharmaVoice
· Jun 18, 2026
· via PharmaVoice
Image: PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Name recognition and "familiarity" with Novo Nordisk's oral Wegovy has contributed to its rapid uptake in its …
The WeekFierceBiotech ↗
In another biotech born out of China's "NewCo" model, cAMPfield Therapeutics has launched with a $180 million …
The WeekBriefing
With pharma M&A and IPOs accelerating, unprepared companies risk missing out as investors demand speed, clean …